Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts
- 15 October 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (20), 6432-6439
- https://doi.org/10.1158/1078-0432.ccr-07-4401
Abstract
Purpose: Non–small cell lung carcinoma (NSCLC) is one of most common malignant diseases and usually is resistant against apoptosis-inducing chemotherapy. This study is to explore the antiapoptotic mechanisms of interleukin (IL)-22 in human lung cancer. Experimental Design: Nineteen cases with stage I to III NSCLC were collected to determine the expression of IL-22. Stable transfection of human IL-22 cDNA into A549 and PG cells and transfection of IL-22-RNA interference (RNAi) into these cancer cell lines were done to reveal the molecular mechanisms of IL-22. Results: It was found that IL-22 was highly expressed in primary tumor tissue, malignant pleural effusion, and serum of patients with NSCLC. IL-22R1 mRNA was also detected in lung cancer tissues as well as lung cancer cell lines. Overexpression of IL-22 protected lung cancer cell lines from serum starvation-induced and chemotherapeutic drug-induced apoptosis via activation of STAT3 and its downstream antiapoptotic proteins such as Bcl-2 and Bcl-xL and inactivation of extracellular signal-regulated kinase 1/2. Exposure to blocking antibodies against IL-22R1 or transfection with the IL-22-RNAi plasmid in vitro resulted in apoptosis of these lung cancer cells via STAT3 and extracellular signal-regulated kinase 1/2 pathways. Furthermore, an in vivo xenograft study showed that administration of IL-22-RNAi plasmids significantly inhibited the human tumor cell growth in BALB/c nude mice. Conclusions: Our study indicates that autocrine production of IL-22 contributes to human lung cancer cell survival and resistance to chemotherapy through the up-regulation of antiapoptotic proteins.Keywords
Other Versions
This publication has 25 references indexed in Scilit:
- IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitroAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomasOncogene, 2004
- Interleukin-22American Journal of Respiratory Cell and Molecular Biology, 2004
- Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activationHepatology, 2004
- Interleukin-10andRelatedCytokines andReceptorsAnnual Review of Immunology, 2004
- Interleukin-22 (IL-22) Activates the JAK/STAT, ERK, JNK, and p38 MAP Kinase Pathways in a Rat Hepatoma Cell LineJournal of Biological Chemistry, 2002
- Inhibition of nuclear factor κB chemosensitizes non–small cell lung cancer through cytochrome c release and caspase activationThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Identification of the Functional Interleukin-22 (IL-22) Receptor ComplexPublished by Elsevier BV ,2001
- Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2–4 and IL-22RPublished by Elsevier BV ,2000
- Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9Published by The American Association of Immunologists ,2000